Sagimet Q1 net loss $10.7M; $175M April financing; Phase 3 acne trial H2 2026

Sagimet Biosciences Inc.

2026-Q1 EPS reported -$0.33

Net loss $10.7M for Q1 2026 vs $18.2M in Q1 2025; R&D expense $7.0M (down from $15.3M YoY).
Cash, cash equivalents and marketable securities $104.5M as of March 31, 2026; expects funding through 2028.
Completed $175M equity financing in April 2026 (29.2M shares at $6.00) to fund acne programs.
Plans to initiate U.S. Phase 3 trial of denifanstat in moderate-to-severe acne in second half 2026.
Phase 1 trial of FASN inhibitor TVB-3567 ongoing; Phase 2 planned after completion subject to regulatory consultation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sagimet Biosciences Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026, was $10.7 million.

Period: the quarter ended March 31, 2026
Net income: Net loss for the quarter ended March 31, 2026, was $10.7 million
Result: reported results

Exact text from the filing

Sagimet Biosciences Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Sagimet Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-059009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.